Characteristics | Total (N=502) N (%) | No ascites (N=477) N (%) | Ascites (N=25) N (%) | P value |
Sex | 0.511 | |||
Female | 229 (45.6) | 216 (45.3) | 13 (52.0) | |
Male | 273 (54.4) | 261 (54.7) | 12 (48.0) | |
Age | 0.301 | |||
<70 | 378 (75.3) | 357 (74.8) | 21 (84.0) | |
≥70 | 124 (24.7) | 120 (25.2) | 4 (16.0) | |
ECOG PS | 0.005 | |||
0 | 237 (47.2) | 232 (48.6) | 5 (20.0) | |
≥1 | 265 (52.8) | 245 (51.4) | 20 (80.0) | |
Primary tumor resection | >0.999 | |||
No | 90 (17.9) | 86 (18.0) | 4 (16.0) | |
Yes | 412 (82.1) | 391 (81.9) | 21 (84.0) | |
Primary tumor sidedness | 0.267 | |||
Left | 172 (34.3) | 166 (34.8) | 6 (24.0) | |
Right | 330 (65.7) | 311 (65.2) | 19 (76.0) | |
NA | ||||
RAS mutational status | 0.048 | |||
All wild type | 317 (63.1) | 296 (62.1) | 21 (84.0) | |
RAS mutated | 165 (32.9) | 161 (33.7) | 4 (16.0) | |
NA | 20 (4.0) | 20 (4.2) | 0 (0.0) | |
BRAF mutational status | 0.054 | |||
All wild-type | 351 (69.9) | 337 (70.6) | 14 (56.0) | |
BRAF mutated | 132 (26.3) | 121 (25.4) | 11 (44.0) | |
NA | 19 (3.8) | 19 (4.0) | 0 (0.0) | |
Synchronous metastases | 0.203 | |||
No | 242 (48.2) | 233 (48.9) | 9 (36) | |
Yes | 258 (51.4) | 242 (50.7) | 16 (64) | |
NA | 2 (0.4) | 2 (0.4) | 0 (0) | |
Liver metastases | 0.246 | |||
No | 306 (61.0) | 288 (60.4) | 18 (72.0) | |
Yes | 196 (39.0) | 189 (39.6) | 7 (28.0) | |
Lung metastases | 0.595 | |||
No | 412 (82.1) | 390 (81.8) | 22 (88.0) | |
Yes | 90 (17.9) | 87 (18.2) | 3 (12.0) | |
Lymphnodal metastases | 0.521 | |||
No | 210 (41.8) | 198 (41.5) | 12 (48.0) | |
Yes | 292 (58.2) | 279 (58.5) | 13 (52.0) | |
Bone metastases | 0.320 | |||
No | 479 (95.4) | 456 (95.6) | 23 (92.0) | |
Yes | 23 (4.6) | 21 (4.4) | 2 (8.0) | |
No of metastatic sites | 0.076 | |||
1 | 227 (45.2) | 220 (46.1) | 7 (28.0) | |
≥2 | 275 (54.8) | 257 (53.9) | 18 (72.0) | |
Prior treatment for metastatic disease | 0.195 | |||
No | 96 (19.1) | 94 (19.7) | 2 (8.0) | |
Yes | 406 (80.9) | 383 (80.3) | 23 (92.0) | |
ICI regimen | 0.525 | |||
a-PD(L)−1 | 332 (66.1) | 314 (65.8) | 18 (72.0) | |
a-PD-1+a-CTLA-4 | 170 (33.9) | 163 (34.2) | 7 (8.0) |
P-values marked with bold indicate statistically significant p-values.
dMMR, mismatch repair deficient; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; mCRC, metastatic colorectal cancer; MSI-H, microsatellite instability high; NA, not available; PS, Performance Status.